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Abstract
Background: Hyperpigmented lesions need the most frequent dermatological consultations, the acquired ones being more effectively treated. Out of 
them, the most common is melasma, which is currently treated with hydroquinone. Our objective was to compare the efficacy of a treatment based on 
Diacetylboldine-DAB, Alpha arbutin and Licorice with hydroquinone 4%.
Material and methods: We carried out a pilot study on 30 Latin patients (skin type III and IV after Fitzpatrick’s classification).  The product under study 
was applied on one side of the face and hydroquinone on the other, during 60 days.
Results:  The study product demonstrated effectiveness comparable to 4% hydroquinone in the 60 days of monitoring time.  The hyperpigmentations are 
of a chronic type and so, considering the formula of the study product, it has the great advantage of permitting use for a prolonged period of time without 
the risk of undesirable side effects such as ochronosis.  Tolerance for the product was excellent as well, both for daytime and night-time formulations, 
and neither irritation reactions nor allergic reactions were present during the period of use.  
Conclusions:  The combined use of active substances is similar and comparable to hydroquinone in a 60 day period.  The foundation can be laid for 
future studies to approach a new investigation with a larger number of patients, in which the use of hydroquinone can be established in comparison with 
this new treatment, so as to allow a statistically significant relationship to be established.  Additionally, by studying a larger number of participants, it 
would allow this new product to be set up as an effective alternative treatment for melasma.
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Introduction
Hyperpigmented lesions, especially on the face, are a 
very common reason for consultation in dermatology. Some 
spots are of the congenital type and others are acquired; the 
latter type is relatively more susceptible to effective treatment. 
Among these we find melasma, ephelides or freckles, lentigi-
nes, postinflammatory hyperpigmentations and others [1].
Melasma or facial chloasma is a commonly acquired 
hyperpigmentation related to an increase in the number and 
activity of clones of melanocytes, when activated by ultraviolet 
light. It appears in exposed areas and can be classified, accor-
ding to location, as centrofacial (the most common), malar 
or mandibular. It can also occur on the neck and forearms 
[1, 2, 3, 4].
This pathology is predominant in the female sex, appea-
ring in 10 women for each man, thus highlighting the role 
played by oestrogen in stimulating melanogenesis, possibly 
by costimulation in the synthesis of melanosomes [5, 6].
Factors such as exposure to the sun, stress, pregnancy, oral 
contraceptives, anti-epileptic drugs, endocrine dysfunction, 
cosmetics, nutritional deficiencies and liver deficiencies have 
been associated with clinical aggravation of melasma [7].
In the physiopathology of the formation of melasmas in 
predisposed persons, the action of sunlight on a chemical sub-
strate in areas exposed to light has been established, with pre-
sentation increasing during periods of exposure to ultraviolet 
rays, and decreasing when the patient avoids ultraviolet rays.
Acute exposure to ultraviolet radiation activates one of the 
most important adaptive mechanisms of the skin, the process 
of inflammation-tanning, as well as inducing pigmentation in 
the areas subjected to damage. The increased deposit of me-
lanin can be epidermal, dermal or a mixture of the two [1, 8].
Diagnosis is essentially clinical and it is indispensable 
that the examination takes place under good lighting. Addi-
tionally, other instruments can be used such as a magnifying 
glass (magnified 7-10x) or a dermatoscope (epiluminescent 
microscope) using wide field objectives with a focal distance of 
10 – 15 cm; magnifications of 10 to 50x are routinely enough to 
permit observation of dermoepidermal pigmentation lesions, 
along with a Wood’s lamp which is a Hg lamp encased in glass 
that emits UV radiation with a peak of 360 nm, enough to 
penetrate into the medium dermis. It allows visualization of 
the level of pigmentation, differentiating epidermal hyperpig-
mentation, which increases the contrast in the lesion, from 
dermal hyperpigmentation, which has no contrast. There is 
a clinical correlation between this procedure and a histopa-
thological biopsy. Instruments can also be used to evaluate 
the color of skin, by the presence of melanin, and that allows 
quantitative evaluation of the treatments used [1, 8, 10].
To treat melasma, suspension of oral contraceptives is 
recommended, whenever possible, although the pigmentation 
may last several years in spite of this. Direct exposure to the 
sun should be avoided, broad-spectrum sunscreen should be 
used and physical measures, such as wearing a hat, should be 
taken. Several products exist for topical use, the most com-
mon being 2 to 4% hydroquinone, considered the standard 
in the Western Hemisphere (prohibited in Japan). It can be 
associated with tretinoin, kojic acid, glycolic acid, arbutin, 
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ascorbic acid, licorice, ellagic acid, azelaic acid, pycnogenol, 
etc. [11, 13, 14].
Hydroquinone is approved by the FDA in humans in 
concentrations equal to or less than 2%, and in higher con-
centrations only under medical supervision.  Other treatments 
can be added such as chemical and mechanical peelings and 
laser treatments [15, 16, 17].
General Objective of the Study: to confirm clinical efficacy 
and tolerance of a treatment based on a formulation with the 
following components: Diacetylboldine - DAB, Alpha Arbu-
tin, and Licorice (see detailed formula in appendix), to reduce 
hyperpigmented lesions of the melanosis or facial melasma 
types, through non-invasive technologies, in Latin women.
Specific Objectives: to compare the efficacy of the pro-
duct in the study to 4% hydroquinone in a compounded 
formulation. To evaluate the number of spots and intensity 
of pigmentation through non-invasive technologies and the 
cosmetic properties of treatments to be used (self-completed 
questionnaire).
Material and methods
An open prospective study was performed on 30 volun-
teers with hyperpigmented lesions that persisted despite 
receiving other treatments, to confirm the clinical efficacy 
of a treatment based on a depigmentation product applied at 
night, formulated with a base of Diacetylboldine - DAB, Alpha 
Arbutin, Licorice, Glycolic Acid, Ascorbic Acid and Salicylic 
Acid, plus a depigmentation product applied during the day, 
formulated with a base of Diacetylboldine - DAB, Beta white®, 
Vitamin C and 50+ sunscreen.
Patients applied products on one half of the face, to com-
pare their effect with hydroquinone in a 4% compounded 
formulation on the other half of the face, for a period of 60 
days. All patients received UV protection with 50+ broad-
spectrum sunscreens (fig. 1).  The parameters to be studied 
were evaluated through clinical examinations, instrumental 
methods and a self-evaluation questionnaire.
The study was performed over a period of 60 days with 
a total of 30 female patient volunteers of Latin background. 
Treatment with the formula took place with applications 
during the day and at night. The test product was applied 
according to the manufacturer’s instructions and a self-eva-
luation questionnaire was used for subjective appreciation 
of the product, cosmetic acceptability of the formulation’s 
appearance, texture and ease of application, presence of greasy 
residue, perception of odour and subjective evaluation of the 
efficacy of the product (reduction of spots). Additionally, 
adverse reactions during the study period (burning, itching 
and peeling) were evaluated and analyzed to determine any 
possible relation to product usage.  Patients were selected in 
accordance with the following criteria:
Inclusion criteria – Female volunteer patients aged between 
30 and 65 years, diagnosed with moderate to severe melasma, 
with or without lentigos or ephelides, who presented resistance to 
other treatments for melasma. They also must have complied with 
the criteria for being under contraceptive treatment or treatment 
for menopause, without a change in hormonal therapy, if any, 
during the 6 months before the study or during the study. They 
must not be pregnant or breast-feeding, not be using topical or 
systemic treatments at the start of the study, nor present a history 
of intolerance to topical products. Also, they were requested to 
abstain strictly from direct exposure to the sun and to sunlamps 
during the study period.
Exclusion criteria – patients undergoing treatment for 
their melasma. Subjects with a history of allergic reactions 
to depigmentation products were also excluded, as well as 
women who presented any systemic or cutaneous pathology 
or who received any medication that might have altered the 
evaluation parameters during the study period. Patients 
must not present active facial lesions, or any history of laser 
treatment, or chemical peeling in the two months prior to the 
study. Patients who may have used isotretinoin in the 6 months 
prior to the study, or who may have used steroids, alpha/beta 
hydroxy acids, or tretinoin in the two months prior to the 
study, were also excluded.
Patients signed an informed-consent form, notifying them 
of what to expect from the experience and of the possible con-
sequences of their participation. It is used to give agreement to 
participate in the study. This consent agreement also informed 
them that participants’ rights would be protected and that the 
data collected would remain confidential, although it may be 
used in an anonymous form in scientific studies. The decision 
to participate was entirely voluntary.
Prospective study that included 30 women volunteers 
of Latin descent, between 30 and 65 years of age, suffering 
from moderate to severe melasma on at least both of their 
cheeks. For the comparison study, a depigmentation product 
for night-time application was used, which was formulated 
on a base of diacetylboldine, alpha arbutin, licorice, glycolic 
acid, vitamin C and salicylic acid (see appendix for formula) 
along with a depigmentation product for daytime application, 
formulated on a base of diacetylboldine, Beta White® (a bio-
mimetic peptide encapsulated in liposomes), vitamin C and 
sunscreen (see appendix for formula). These products were 
compared with a cream in a compounded formula associa-
ted with 4% hydroquinone. Face cleanser, humectant-based 
cream and 50+ invisible fluid sunscreen were used as part 
of the regular daily routine. This study was approved by the 
research ethics committee.
A Wood’s lamp was used to determine the type of melas-
ma, and a melanometer (Mexameter) from Khazaka-Courage 
was used to measure the quantity of melanin and to report 
the results obtained as a numerical value. The VISIA system 
was also used to evaluate pigmentation, along with other skin 
parameters. This system photographs the forehead and right 
and left sides of the face, which are evaluated by the system’s 
software, which then issues numerical values that relate to 
average values in the general population of the same age and 
skin type. It also evaluates the effect of the applied treatments 
by comparing values issued by the system before and after 
application of the product in the study.
Digital photos were taken before and after treatment and 
a subjective evaluation was made by the participating patients 
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(self-evaluation). Skin phototypes were determined using the 
Fitzpatrick scale.
Types of skin:
I.  Always burns, never tans 
II.  Always burns, tans slightly 
III.  Sometimes burns, always tans
IV.  Never burns, always tans
V.  Always deeply pigmented
VI.  Black
Volunteers were evaluated on D 0 and D 60.  At the initial 
visit patients were examined to clinically determine the type of 
melasma with a Wood’s lamp, and parameters were measured 
by melanometer and with VISIA.
Pigmented lesions present on the right and left cheeks were 
evaluated clinically and classified as follows:
++++ If pigmented lesions were detected on 75% to 100% 
of the malar area.
+++ If lesions cover 50% to 75% of the malar area.
++ If lesions cover 25% to 75% of the malar area.
+ If lesions cover less than 25% of the malar area.
Digital photos were taken, and the products included in 
the protocol were delivered with instructions in their use.
Participants were instructed to report any discomfort 
that might be due to use of the study product, or if they had 
questions about their use.
At night, skin cleansing and application of the study 
product on the right side of the face and the compounded 
product on the left side, according to the attached diagram.
In the morning, skin cleansing and application of the 
study product on the right side of the face and base cream 
on the left side.
50+ fluid sunscreen on the whole face.  Make-up as usual. 
In the examination after 60 days the same parameters were 
evaluated.
Results
At the beginning of the study the group of patients suffe-
ring from facial hyperpigmentation was composed of 30 heal-
thy women, from 33 to 65 years of age, averaging 46,6 years of 
age, who met the inclusion criteria. 29 of them completed the 
study.  One patient did not attend the examinations because 
of an illness unrelated to the study in progress.
The Wood’s lamp test was applied to the patients, the 
result of which was compatible with pigmentation mostly of 
an epidermal character, making clear a major contrast with 
the pigmented areas when illuminated with this wavelength. 
Patient 17 did not attend the examinations.
As we see in table 1 of clinical measurement, of the 29 pa-
tients who completed the study, 11 patients improved on both 
sides of the face, 8 patients remained the same on both sides, 5 
patients improved only on the right side, corresponding to the 
study product, 3 patients remained the same on the right side, 
corresponding to the study product, 2 patients worsened on 
the right side, corresponding to the study product, 3 patients 
improved only on the left side of the face, corresponding to 
hydroquinone, 7 patients remained the same only on the left 
side of the face, corresponding to hydroquinone.  No patient 
worsened with the use of hydroquinone.  An example of the 
clinical result can be seen in figure 2.
This measurement shows the pigmentation in the evalua-
ted areas in numerical values, numbers that are correlated with 
clinical evaluation. The pigmented lesions do not disappear, 
but they do decrease in intensity.  The effect can be seen in 
figure 3 (results with VISIA).
In this table we can see the measurement of melanin on 
the right and left halves of the face, in which measurements 
at 4 points on each cheek are averaged. A numerical figure 
is given that allows comparison of the intensity of melanin 
pigmentation on the cheek before and after treatment.
A comparative study was made through percentage vari-
ance analysis, with the numerical data issued by VISIA (tab. 
2, 3).  With this data we can emphasise the fact that a 19.7% 
improvement was made with respect to the initial value in 
the group of patients who showed improvement with the 
study product.
By the same analysis, in the patients that improved with 
hydroquinone, an 18.3% improvement was made with respect 
to the initial value.
In general, in the self evaluation, patients reported that the 
melasma affected their quality of life, a significant percentage 
going so far as to admit they use make-up to try to cover the 
damaged areas (fig. 4, 5).
Moderate itching and burning were described as adverse re-
actions to use of the study product, but not to the point of causing 
participants to decide to discontinue using the product (fig. 6, 7, 
8). Furthermore, improvement was shown in areas such as skin 
texture, increased shine, and improved appearance, even though 
the hyperpigmented lesions did not necessarily disappear. This 
effect can also be seen in digital photos as in figure 2.
Even though minor adverse reactions existed that were well 
tolerated by patients, the majority of them stated that because 
of the improvement in skin quality from using the product 
for the established period of time, they would continue to 
use the product for a longer time. The cosmetic properties of 
the study product were very well evaluated by the patients.
FORMULAS OF STUDY PRODUCTS
Night time:
• Glycolic Acid 6% 
• LumiskinTM 4% (Diacetylboldine - DAB) 
• Vitamin C (ascorbyl tetraisopalmitate) 2% 
• Alpha Arbutin 2% 
• Salicylic Acid 0.1% 
• Licorice 0.1% 
Day time:
• Beta white® 5% (Bio-mimetic peptide encapsulated in 
liposomes) 
• Lumiskin™ 4% (Diacetylboldine - DAB) 
• Vitamin C (ascorbyl tetraisopalmitate)1% 
• Eusolex 15% 
• Tinosorb M 9% 
• Tinosorb S 1.5% 
• Titanium Dioxide 2%
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Conclusions
The study product demonstrated effectiveness comparable 
to 4% hydroquinone in the 60 days of monitoring time.
We know that the hyperpigmentations are of a chronic 
type and so, considering the formula of the study product, 
it has the great advantage of permitting use for a prolonged 
period of time without the risk of undesirable side effects 
such as ochronosis.
Tolerance for the product is excellent as well, both for 
daytime and night-time formulations, and neither irritation 
reactions nor allergic reactions were present during the pe-
riod of use.
With our study, the foundation can be laid for future 
studies to approach a new investigation with a larger number 
of patients, in which the use of hydroquinone can be establi-
shed in comparison with this new treatment, so as to allow a 
statistically significant relationship to be established. Additi-
onally, by studying a larger number of participants, it would 
allow this new product to be set up as an effective alternative 
treatment for melasma.
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